Keyphrases
90-day Mortality
27%
Acute Atrial Fibrillation
18%
Acute Kidney Injury
36%
All-cause Mortality
9%
Anti-Xa Activity
18%
Anticoagulants
9%
Area under the Receiver Operating Characteristic Curve
11%
Arterial Waveform Analysis
7%
Bioaccumulation
12%
Cardiac Index
18%
Cardiac Output
10%
Cardiac Output Monitoring
18%
Circulatory Shock
18%
Clinical Analysis
36%
Clinical Examination
36%
Clinical Signs
9%
Confidence Interval
20%
Critical Care Outcomes
18%
Critical Care Ultrasonography
22%
Critical Care Ultrasound
18%
Critically Ill
18%
Critically Ill Patients
78%
Deep Clustering
18%
Diagnostic Accuracy
18%
Error Grid Analysis
18%
FloTrac
18%
Haloperidol Decanoate
18%
Hemodynamically Unstable
12%
Intensive Care
36%
Intensive Care Unit
18%
Intensive Care Unit Patients
12%
Intermediate Dose
42%
International Survey
18%
Low Molecular Weight Heparin
48%
Lower Extremity Deep Venous Thrombosis
18%
Major Bleeding
9%
Mortality Prediction
18%
Nadroparin
21%
Oral Intoxication
18%
Patients with COVID-19
18%
Placebo
7%
Prospective Observational Study
18%
Recurrent Venous Thromboembolism
9%
Relative Risk
11%
Risk of Bias
7%
Systematic Meta-analysis
36%
Thromboprophylaxis
63%
Ultra-low Dose
42%
Venous Thromboembolism
25%
Venous Thromboembolism Prevention
22%
Medicine and Dentistry
Activated Charcoal
7%
Acute Kidney Injury
18%
Adverse Event
6%
All Cause Mortality
6%
Antiarrhythmic Agent
6%
Anticoagulant
24%
Arterial Pressure
7%
Atrial Fibrillation
22%
Auscultation
18%
Clinical Examination
77%
Cohort Analysis
24%
Crackle
7%
Deep Vein Thrombosis
18%
Diagnosis
12%
Diagnostic Accuracy
22%
Direct Oral Anticoagulant
12%
Echography
47%
Haloperidol Decanoate
18%
Heart Output
24%
Heart Output Measurement
18%
Hemodynamic
17%
Heparin
12%
Ingestion
7%
Intensive Care
100%
Intensive Care Unit
24%
Low Molecular Weight Heparin
9%
Lower Extremity Deep Vein Thrombosis
18%
Lung Auscultation
18%
Major Bleeding
9%
Meta-Analysis
36%
Network Meta-Analysis
18%
New-Onset Atrial Fibrillation
18%
Observational Study
20%
Patient-Data
18%
Pentasaccharide
6%
Physician
8%
Placebo
12%
Prognostic Factor
18%
Prospective Cohort Study
18%
Pulmonary Edema
15%
Pulmonary Embolism
18%
Randomized Controlled Trial
6%
Rhonchi
7%
Rhythm
7%
Sequential Analysis
9%
Shock (Circulatory)
40%
Subgroup Analysis
8%
Systematic Review
18%
Thrombosis Prevention
20%
Venous Thromboembolism
36%
Pharmacology, Toxicology and Pharmaceutical Science
Activated Carbon
7%
Acute Kidney Failure
54%
Adverse Event
15%
All Cause Mortality
18%
Anticoagulant Agent
20%
Bioaccumulation
11%
Bleeding
18%
Deep Vein Thrombosis
20%
Direct Oral Anticoagulant
12%
Forward Heart Failure
6%
Haloperidol Decanoate
18%
Heparin
12%
Kidney Disease
18%
Low Molecular Weight Heparin
54%
Lower Extremity Deep Vein Thrombosis
18%
Lung Embolism
20%
Nadroparin
20%
Pentasaccharide
6%
Placebo
20%
Prospective Cohort Study
20%
Randomized Controlled Trial
10%
Replacement Therapy
5%
Shock
18%
Thrombosis
83%
Toxic Injury
18%
Venous Thromboembolism
80%
